Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Henan Cancer Hospital

63 clinical trials

41 abstracts

Abstract
Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).
Org: Sun Yat-sen University Cancer Center (China), Rui Jin Hospital Affiliated to Shanghai Jiao Tong University, Jinagsu Province Institute of Cancer Research, The University of Texas MD Anderson Cancer Center, Chongqing University Cancer Hospital,
Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Abstract
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.
Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Second Department of Thoracic Tumors, Peking University Cancer Hospital, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology,
Abstract
Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.
Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Fudan University Shanghai Cancer Center, The Affliated Cancer Hospital of Zhengzhou University,
Abstract
ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma.
Org: Musculoskeletal Tumor Center, Peking University People's Hospital, Tianjin Medical University Cancer Institute and Hospital, Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study.
Org: Peking University Cancer Hospital & Institute, Henan Cancer Hospital, Fudan University Shanghai Cancer Center, Fujian Provincial Cancer Hospital, Zhejiang Cancer Hospital,
Abstract
A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.
Org: Fudan University Shanghai Cancer Center, The Second Hospital of Dalian Medical University, Harbin Medical University Cancer Hospital, Liaoning Cancer Hospital & Institute, Shenyang, China, Hunan Cancer Hospital,
Abstract
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.
Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Harbin Medical University Cancer Hospital,
Clinical trial
A Single Arm, Multi-center, Phase Ib/II Clinical Trial of PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-06-30
Abstract
Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Org: Institute of Hematology and Blood Disease Hospital, CAMS & PUMC, Tianjin, China, Henan Cancer Hospital, Zhengzhou, China, The Second Hospital of HeBei Medical University, Shijiazhuang, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Institute of Hematology and Oncology, Harbin the First Hospital, Harbin, China,
Clinical trial
Adjuvant Capecitabine Metronomic Chemotherapy Plus Endocrine Therapy for HR-positive, HER2-negative, Primary Breast Cancer: a Multicenter, Randomized, Double-blind Phase III Clinical Trial
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Camrelizumab Plus Cisplatin in Advanced Cutaneous Squamous Cell Carcinoma: a Single-arm, Open, Single-center Phase II Study
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Single-Arm, Phase II Study of AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Non Inferior, Randomized Controlled Phase II Clinical Study Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
Status: Recruiting, Estimated PCD: 2025-05-03
Abstract
Neoadjuvant therapy using PD-1 inhibitor plus chemotherapy with different intervals between chemotherapy cycles for locally advanced gastric or gastroesophageal junction cancer: A randomized phase 2 study.
Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Department of Immunology and Oncology, Clínica Universidad de Navarra, Henan Cancer Hosptal, Surgical Oncology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University,
Abstract
Clinical efficacy and safety analysis of immune checkpoint inhibitors combined with concurrent chemoradiotherapy for stage IIIC1-IVA cervical cancer: A prospective cohort study.
Org: Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Cancer Hospital,
Clinical trial
Toripalimab Combined With FLOT Regimen in Locally Advanced Gastric cancer-a Prospective, Open, Multi-center, Phase Ⅱ Clinical Study
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2026-05-31
Abstract
Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.
Org: Lymphatic Comprehensive Internal Medicine Ward, Henan Cancer Hospital, Henan Cancer Hospital, Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China,
Abstract
A phase I clinical trial investigating the safety, tolerability, and pharmacokinetics of HX301 (narazaciclib), a novel multi-kinase inhibitor targeting CSF1R, CDK 4/6, and ARK5, in patients with advanced solid tumors.
Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).
Org: Next Oncology Virginia and Virginia Cancer Specialists, Henry Ford Cancer Institute, Detroit, MI, UC Davis Comprehensive Cancer Center, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Henan Cancer Hospital,
Clinical trial
A Clinical Study of Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR Positive HER2 Positive Breast Cancer
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Prospective, Open-label Explorative Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Status: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
The Efficacy and Safety of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumors: a Prospective Single-arm Clinical Study
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Comparing TP (Docetaxel + Cisplatin) and TAC (Docetaxel + Doxorubicin + Cyclophosphamide) in Neoadjuvant Therapy for Operable Triple Negative Breast Cancer, A Multicenter, Randomized, Phase II Clinical Trial
Status: Completed, Estimated PCD: 2022-11-26
Clinical trial
A Non-inferior, Randomized Controlled Phase III Clinical Study Comparing the Efficacy of TCbHPand ECHP-THP in Neoadjuvant Treatment of Operable HER2-positive Breast Cancer
Status: Withdrawn, Estimated PCD: 2023-03-28
Clinical trial
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer: a Single Arm, Dual Cohort, Prospective, Open Phase II Exploratory Study
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Carrellizumab Combined With Albumin-binding Paclitaxel in the Treatment of Locally Late Stage or Relapsed Metastatic Cutaneous Squamous Cell Carcinoma: a Single-arm, Open, Multicenter, Prospective Clinical Study
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Multicenter, Double-blind, Randomized Controlled Phase II Clinical Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity
Status: Completed, Estimated PCD: 2022-04-21
Clinical trial
A Randomized, Open-label, Multicentre Clinical Study of TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
Status: Recruiting, Estimated PCD: 2025-10-15
Clinical trial
A Single-center, Open-arm, Single-arm Phase II Trial of the PD-1 Antibody Tirelizumab Plus Dacarbazine as First-line Treatment for Advanced Melanoma
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Relapse and Refractory Patients With CD19+/CD20+ Non-Hodgkin's Lymphoma (NHL)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Prospective, Randomized Clinical Study of the Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) With Thalidomide
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Prospective, Single Center, Phase II Study of Disitamab Vedotin（RC48) Combined With Sintilimab Plus XELOX for Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Clinical Study of Cadonilimab(PD-1/CTLA-4 Bi-Specific Antibody) in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Patients With Stage Ⅳ Breast Cancer
Status: Withdrawn, Estimated PCD: 2022-05-01
Clinical trial
Phase II Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2025-12-20
Clinical trial
A Multicenter, Single Arm Clinical Study on the Efficacy and Safety of the "ITIVA" Protocol in Patients With Complete Remission of AML at Initial Diagnosis
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer Receiving Anthracycline/Cyclophosphamide-containing Chemotherapy
Status: Completed, Estimated PCD: 2023-08-15
Clinical trial
Phase II Clinical Trial of Camrelizumab Combined With AVD (Epirubicin, Vincristine and Dacarbazine) in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Comparing the Efficacy and Security of Nab-PHP and TCbHP in Neoadjuvant Chemotherapy for HER2 Positive Operable Breast Cancer , A Multicenter, Randomized, Phase III Clinical Trial
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Single-arm, Multi-center, Phase II Clinical Trial of R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Medium to High Risk/High Risk Diffuse Large B Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-11-29
Clinical trial
Prospective Single-arm, Single-center Exploratory Clinical Study on Efficacy and Safety of Interventional Therapy Combined With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Serplulimab Plus Bevacizumab and Chemotherapy for EGFRm+ Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer，Single Arm, Multicenter Phase II Clinical Study
Status: Not yet recruiting, Estimated PCD: 2026-01-31
Clinical trial
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
Status: Active (not recruiting), Estimated PCD: 2021-11-04
Clinical trial
A Controlled, Phase II Study of Anlotinib vs Placebo Combination With Vinorelbine for the Treatment of HER2- Advanced Breast Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer : a Single-arm, Open-label, Ahead Study
Status: Active (not recruiting), Estimated PCD: 2021-04-16
Clinical trial
Sintilimab Combined With Anlotinib as Second- or Further-line Therapy for Extensive Disease Small Cell Lung Cancer: A Prospective, Single-arm, Phase II Study
Status: Completed, Estimated PCD: 2023-05-01
Clinical trial
A Single-arm, Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Sintilimab and CAPEOX as 1L Treatment for Advanced Unresectable or Metastatic G/GEJ Cancer (FUNCTION Research)
Status: Recruiting, Estimated PCD: 2025-12-15
Clinical trial
An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Study of the Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Status: Not yet recruiting, Estimated PCD: 2027-12-30
Clinical trial
A Phase 2 Study to Investigate the Safety, Tolerability and Anti-tumor Activity of Golidocitinib in Combination With CHOP as the Front-line Treatment for Participants With Peripheral T-cell Lymphomas (PTCL)
Status: Recruiting, Estimated PCD: 2025-07-30
Clinical trial
A Single Arm, Multi-center, Phase II Clinical Trial of Rituximab, Lenalidomide Combined With High-dose Methotrexate and Temozolomide (RL-MT) in the First-line Treatment for Patients With Primary Central Nervous System Lymphoma
Status: Recruiting, Estimated PCD: 2024-01-13
Clinical trial
Clinical Study on Efficacy, Safety and Cytopharmacokinetics of RD13-02 Cell Injection in the Treatment of Patients With Recurrent or Refractory CD7-positive Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-06-07
Clinical trial
A Single Arm, Phase II Clinical Trial of Orelabrutinib Combined With Pemetrexed in the Treatment for Patients With Relapsed/Refractory Central Nervous System Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-21
Clinical trial
A Single Arm, Multi-center, Phase II Clinical Trial of Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma and CD79A/CD79B Genetic Abnormality
Status: Recruiting, Estimated PCD: 2023-12-25
Clinical trial
A Single Arm, Multi-center, Phase II Clinical Trial of VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Single-center, Randomized, Self-controlled Exploratory Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer
Status: Recruiting, Estimated PCD: 2024-12-28
Clinical trial
Phase I b/ II Clinical Study of Iribrine Mesylate Plus Tucidinostat in the Treatment of HR+/HER2- Locally Relapsed or Metastatic Breast Cancer After Previous CDK4/6 Inhibitor Failure
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Study to Evaluate the Efficacy and Safety of Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-05-30
Clinical trial
A Multicenter, Open, One-arm Phase II Study of Ranvastinib Mesylate Capsules in the Treatment of Advanced Bone and Soft Tissue Sarcoma After Chemotherapy Failure
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Single Arm, Single Center, Prospective Clinical Study of Anrotinib Hydrochloride Combined With Doxorubicin in the Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2021-08-23
Clinical trial
Single-arm, Open, Exploratory Clinical Study on the Safety and Efficacy of Piamprilimab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage
Status: Not yet recruiting, Estimated PCD: 2025-02-25
Clinical trial
Phase II Study Serplulimab Combined With Neoadjuvant Chemotherapy for Early-stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Status: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
Phase II Clinical Study of PD1 Antibody (SHR-1210) Combined With Trastuzumab, Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A Single Arm, Exploratory Clinical Study on the Prevention of Bone Marrow Suppression Caused by Platinum Containing Chemotherapy in Advanced Non-small Cell Lung Cancer With Trilaciclib
Status: Not yet recruiting, Estimated PCD: 2025-04-30
Abstract
IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04).
Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, The Third Affiliated Hospital Of Qiqihar Medical University, Shandong Provincial Institute of Cancer Prevention and Treatment, Henan Cancer Hospital, Shanghai Lung Cancer Center,
Abstract
Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
Org: Peking University Cancer Hospital & Institute, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, The Third People's Hospital of Zhengzhou, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China,
Abstract
Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.
Org: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Affiliated Dongguan Hospital, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital,
Abstract
A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer.
Org: Innovative Cellular Therapeutics Co., Ltd., Stem Cell and Cancer Center, the First Bethune Hospital of Jilin University, Henan Cancer Hospital, First Affiliated Hospital of Jilin University,
Abstract
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies.
Org: Henan Cancer Hospital, BeiGene (Shanghai) Co., Ltd., BeiGene (Shanghai) Co., Ltd. Shanghai, BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene USA, Inc., San Mateo, CA,
Abstract
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.
Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea,
Abstract
Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC).
Org: Jilin Cancer Hospital, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Henan Cancer Hospital, Yunnan Cancer Hospital, Kunming, Yunnan, China,
Abstract
A phase 1, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10382 (TERN-701) in patients (pts) with chronic myeloid leukemia (CML).
Org: Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Nanfang Hospital, Phase I Clinical Research Room,Nanfang Hospital Southern Medical University, Guangzhou, China,
Abstract
A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors.
Org: Fudan University Shanghai Cancer Center, Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Department of Hematology ,ZheJiang provincial people’s hospital, Department of Oral and Maxillofacial Head & Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China,
Abstract
SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.
Org: Sun Yat-sen University Cancer Center Gansu Hospital, First Affiliated Hospital of Gannan Medical University, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, The Second People's Hospital of Yibin City, Fudan University Shanghai Cancer Center,
Abstract
Study on the mechanism of CXCR3 expression in paracancer and tumor tissues of colon cancer patients.
Org: The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Cancer Hospital,
Abstract
Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).
Org: Fudan University Shanghai Cancer Center, Henan Cancer Hospital, Union Hospital Medical College Huazhong University of Science and Technology, Guangdong Provincial People's Hospital, Chinese People’s Liberation Army General Hospital,
Abstract
Huaier granules for hepatocellular carcinoma recurrence after ablation: A multicenter prospective cohort study.
Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Beijing Youan Hospital, Capital Medical University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,
Abstract
A retrospective cohort study examining the effects of anti–PD-1 antibody in combination with apatinib in patients previously treated for HER2-negative advanced gastric/gastroesophageal junction cancer.
Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,
Abstract
Analysis of short-term efficacy and safety of mitoxantrone hydrochloride liposome regimen therapy in adult acute myeloid leukemia.
Org: Department of Hematology & Oncology, College of Medicine, University of Oklahoma Health Sciences Center, Harbin Institute of Hematology & Oncology, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Tangdu Hospital, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Abstract
Clinical analysis of immunotherapy rechallenge in advanced gastric cancer.
Org: Henan Cancer Hospital, China National Biotec Group, Zhengzhou Gensciences, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,
Abstract
First-in-human study of ZG005, a dual specific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.
Org: Jilin Cancer Hospital, Changchun, China, Department of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China, Shulan (Hangzhou) Hospital, Hangzhou, China,
Abstract
Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.
Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study.
Org: Sun Yat-sen University Cancer Center Gansu Hospital, Harbin Medical University Cancer Hospital, Henan Cancer Hospital, Peking University First Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China,
Abstract
Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.
Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group,
Abstract
Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer:  CRUISER study.
Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Henan Cancer Hospital,
Abstract
A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice.
Org: Tongji University Shanghai East Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Zhejiang Cancer Hospital, Chinese Academy of Sciences,
Abstract
Study of microwave ablation in patients with unresectable soft tissue sarcoma.
Org: Henan Cancer Hospital, Zhengzhou Gensciences,
Abstract
Effect of reducing the number of neoadjuvant chemoimmunotherapy cycles on clinical efficacy in locally advanced PD-L1 positive gastric cancer: A single center phase 2 study.
Org: Department of Immunology and Oncology, Clínica Universidad de Navarra, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Department of Gastrointestinal Surgery, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong, China, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial.
Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Anyang Cancer Hospital, Anyang, China, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital of Henan University of Science and Technology,
Abstract
A phase ll study on the neoadjuvant treatment of resectable high-risk soft tissue sarcoma with anlotinib and doxorubicin.
Org: Henan Cancer Hospital, Zhengzhou Gensciences,
Abstract
KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.
Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Oncology Department, the First Affiliated Hospital of Xinxiang Medical College, Chongqing University Three Gorges Hospital & Chongqing Three Gorges Central Hospital, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tianjin Medical University Cancer Institute & Hospital,National Clinical Research Center for Cancer,
Clinical trial
An Investigator-initiated Trial Evaluating the Efficacy and Safety of Anti-Trop2 Universal CAR-NK(U-CAR-NK) Cells Therapy Combined With Chemotherapy for Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Not yet recruiting, Estimated PCD: 2026-07-31
Clinical trial
A Phase II Study of the Efficacy and Safety of SHR-A1921 or SHR-A2009 in Patients With Previously Treated Advanced NSCLC
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
The Efficacy and Safety of Pyrotinib Plus Capecitabine in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients With Active Brain Metastases That Have Failed Antibody-drug Conjugate(ADC): a Prospective, Single Arm, Trial
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Single-Arm, Prospective, Open Clinical Study of Palbociclib for Backline Treatment of Advanced Hepatocellular Carcinoma
Status: Recruiting, Estimated PCD: 2026-01-15
Clinical trial
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of L218CAR19 in Patients With CD19 Positive Relapsed/Refractory B-cell Lymphomas
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Single Arm, Multicenter Phase II Clinical Study of TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Oxaliplatin, Capecitabine in the First-line Treatment of Advanced Gastric Cancer (GC) or Adenocarcinoma of Esophagogastric Junction (AEG)
Status: Active (not recruiting), Estimated PCD: 2024-12-01